glp 1 fiber supplement Optimal GLP-1 – Optimal Health Systems 6g fibre and 0g sugar in every handy stick pack GLP-One Support, Prebiotic Fiber Powder,

Description

These large correlative epidemiological findings support a potential effect of GLP-1 on drug craving

These components work synergistically to support a healthy gut microbiome

Active Ingredient : Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Unique Dual-Action Mechanism : According to FDA prescribing information and pharmacological literature, tirzepatide represents the first medication to activate both GIP and GLP-1 receptors simultaneously, providing enhanced metabolic effects compared to single-receptor activation: GLP-1 Receptor Activation Effects : Glucose-dependent insulin secretion enhancement Glucagon secretion suppression Gastric emptying delay Central appetite regulation GIP Receptor Activation Effects : Additional glucose-dependent insulin secretion enhancement Potential effects on fat metabolism Synergistic weight loss effects with GLP-1 activation May improve beta cell function Clinical Trial Evidence - SURMOUNT Program : According to published data from the SURMOUNT-1 trial (New England Journal of Medicine, 2022): Study Design : 72-week randomized, double-blind, placebo-controlled trial 2,539 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Interventions: Once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg doses) Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results (15 mg dose): Tirzepatide 15 mg group: Average 20.9% body weight loss (approximately 46 lbs for 220 lb individual) Placebo group: Average 3.1% body weight loss (approximately 7 lbs for 220 lb individual) Difference: 17.8 percentage points (p0.001 for superiority) Dose-Response Results : Tirzepatide 5 mg: Average 15.0% body weight loss Tirzepatide 10 mg: Average 19.5% body weight loss Tirzepatide 15 mg: Average 20.9% body weight loss Secondary Results (15 mg dose): 62.7% of tirzepatide 15 mg participants lost 20% body weight (vs 1.3% placebo) 89.4% lost 10% body weight (vs 16.6% placebo) 96.0% lost 5% body weight (vs 34.3% placebo) Clinical Comparison Limitation: The SURMOUNT trials studying tirzepatide and STEP trials studying semaglutide were conducted separately with different methodologies, time periods, and participant populations

Eli Lilly reiterated to NPR that the drugs have been "available since August." "Our current manufacturing investment of over $20 billion in the past four years is the most significant in our history, and will allow us to continue increasing capacity to safely bring these medicines to people who need them," Eli Lilly spokesperson Courtney Kasinger wrote in an email